54232-03-0

Basic information

• Product Name: 2-BROMO-5-HYDROXY-3-PICOLINE
• Synonyms: 2-BROMO-5-HYDROXY-3-PICOLINE;2-Chloro-5-hydroxy-3-methylpyrdine;2-Chloro-5-hydroxy-3-methylpyridine;6-bromo-5-methylpyridin-3-ol;6-chloro-5-Methylpyridin-3-ol;6-chloro-5-Methyl-3-Pyridinol;2-Chloro-3-methyl-5-hydroxypyridine;3-Pyridinol,6-bromo-5-methyl-
• CAS NO: 54232-03-0
• Molecular Formula: C₆H₆ClNO
• Molecular Weight: 188.02194
• Product Categories: Pyridine;1003711-43-0 oldold;MFCD09839267 oldold;2-Bromo-5-hydroxy-3-methylpyridine oldold
• Mol File: 54232-03-0.mol

Chemical Properties

• Boiling Point: 352.96 °C at 760 mmHg
• Flash Point: 167.264 °C
• Appearance: /
• Density: 1.313 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.81±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-5-HYDROXY-3-PICOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-5-HYDROXY-3-PICOLINE(54232-03-0)
• EPA Substance Registry System: 2-BROMO-5-HYDROXY-3-PICOLINE(54232-03-0)

Safety Data

• Hazardous Substances Data: 54232-03-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-Bromo-5-Hydroxy-3-Picoline is used as a research compound for the development of new pharmaceuticals. Its unique chemical structure and properties make it a valuable tool in the synthesis of various drug molecules.
Used in Chemical Research:
2-Bromo-5-Hydroxy-3-Picoline is used as a reagent in chemical research, particularly in the synthesis of complex organic molecules and the study of reaction mechanisms. Its electron-rich nature allows it to participate in various chemical reactions, making it a useful building block in the synthesis of novel compounds.
Note: Since the provided materials do not mention specific applications in different industries or the safety, toxicity, or environmental effects of 2-Bromo-5-Hydroxy-3-Picoline, the uses listed above are based on the general properties and potential applications of pyridine derivatives in research.

InChI:InChI=1/C6H6ClNO/c1-4-2-5(9)3-8-6(4)7/h2-3,9H,1H3

Upstream product

• 38186-82-2 6-chloro-5-methylpyridin-3-amine 
• 1003043-40-0 (6-chloro-5-methylpyridin-3-yl)boronic acid 
• 54232-04-1 6-chloro-5-methylpyridine-3-yl acetate 
• 22280-56-4 2-chloro-3-methyl-5-nitropyridine 

Downstream Products

• 74650-80-9 5-benzyloxy-2-chloro-3-methylpyridine 
• 74650-70-7 2-chloro-5-methoxy-3-methylpyridine 
• 74650-73-0 2-chloro-3-cyano-5-methoxypyridine 
• 74650-71-8 2-chloro-5-methoxy-3-pyridinecarboxylic acid 
• 74650-76-3 5-benzyloxy-2-chloronicotinonitrile 
• 74650-77-4 (S)-5-benzyloxy-2-(3-t-butylamino-2-hydroxypropoxy)nicotinonitrile 
• 1624607-03-9 2-chloro-5-((4-methoxybenzyl)oxy)-3-methylpyridine 
• 228867-86-5 5-hydroxy-3-methylpyridine-2-carbonitrile 
• 1624607-04-0 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine 

Relevant articles and documents

First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump

Overexpression of efflux pumps is an important mechanism of bacterial resistance that results in the extrusion of antimicrobial agents outside the bacterial cell. Inhibition of such pumps appears to be a promising strategy that could restore the potency of existing antibiotics. The NorA efflux pump of Staphylococcus aureus confers resistance to a wide range of unrelated substrates, such as hydrophilic fluoroquinolones, leading to a multidrug-resistance phenotype. In this work, approximately 150 heterocyclic boronic species were evaluated for their activity against susceptible and resistant strains of S. aureus. Twenty-four hit compounds, although inactive when tested alone, were found to potentiate ciprofloxacin activity by a 4-fold increase at concentrations ranging from 0.5 to 8 μg/mL against S. aureus 1199B, which overexpresses NorA. Boron-free analogues showed no biological activity, thus revealing that the boron atom is crucial for biological activity. This work describes the first reported efflux pump inhibitory activity of boronic acid derivatives.

Halogenated allyl amine type SSAO/VAP-1 inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a halogenated allyl amine type compound shown as a formula I, medically acceptable salt, ester or stereo isomers thereof, wherein R1, R2, R3, R4, R5, R6, L1, Cy1, R7 and p are defined in description. The invention also relates to a medicine preparation containing the compounds, a medicine composition containing the compounds, and application of the compounds to prevention and/or treatment on diseases relevant to SSAO/VAP 1 protein or diseases caused by SSAO/VAP 1 protein mediating. The formula I is shown in the description.

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

3-Pyridyl enantiomers and their use as analgesics

The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: STR1 or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

2-SUBSTITUTED PROPOXY-3-CYANO-5-HYDROXYPYRIDINES AND USE AS ANTIHYPERTENSIVES

The present application discloses certain 2-substituted propoxy-3-cyano-5-hydroxypyridines. The compounds have pharmaceutical activity e.g. as antihypertensives.

2-Substituted propoxy-3-cyano-5-RO-pyridines and intermediates

The present application discloses 2-substituted propoxy-3-cyano-5-RO-pyridines and intermediates therefor. The former compounds have pharmaceutical activity.

Synthesis of 2-Chloro-5-hydroxynicotinonitrile: The Required Intermediate in the Total Synthesis of a Hydroxylated Metabolite of (S)-2-(3-t-Butylamino-2-hydroxypropoxy)-3-cyanopyridine

A convenient method for the synthesis of 2-chloro-5-hydroxynicotinonitrile (10) via 5-amino-2-chloro-3-methylpyridine (3) is described.Subsequent conversions provided the basic metabolite 2 of (S)-2-(3-t-butylamino-2-hydroxypropoxy)-3-cyanopyridine (1). 1